Fifth disease
☆ AI Dermatology — Free Service
Emiphumeleni ka-2022 ye-Stiftung Warentest evela eJalimane, ukwaneliseka kwabathengi nge-ModelDerm bekungaphansi kancane kunokuxhumana okukhokhelwayo kwe-telemedicine.
Emiphumeleni ka-2022 ye-Stiftung Warentest evela eJalimane, ukwaneliseka kwabathengi nge-ModelDerm bekungaphansi kancane kunokuxhumana okukhokhelwayo kwe-telemedicine.
Oneminyaka engu-16 ubudala onegciwane le-Fifth disease ― Zombili izihlathi ziba bomvu, kubonakala sengathi ziyashaywa, bese kuvela amaqubuka e-maculopapular emzimbeni.
Erythema ezihlathini zombili.
relevance score : -100.0%
Referencesi-Fifth disease, eyaziwa nangokuthi i-erythema infectiosum, ukutheleleka ngegciwane okubangelwa i-human parvovirus B19. Kuvame kakhulu ezinganeni, ngokuvamile kuthinta lezo eziphakathi kweminyaka engu-4 kuya kwengu-14 ubudala. Izimpawu zivame ukuqala ngomkhuhlane omncane, ikhanda elibuhlungu, umphimbo obuhlungu kanye nemizwa efana nomkhuhlane. Izingane zingase zibe nokuqubuka okubomvu okuhlukile ebusweni obufana ne‑‘slapped cheeks’, kanye nokuqubuka okuyiphethini emzimbeni, ezandleni nasemilenzeni. Kubantu abadala, ubuhlungu obuhlangene buwumkhuhlane ovamile, ongase uvele amasonto ngemva kokutheleleka kokuqala. Ngokuphawulekayo, cishe amaphesenti angu‑20 kuya ku‑30 abantu abadala abathintekile yi‑parvovirus B19 bangase bangabonisi noma yiziphi izimpawu.
Fifth disease (erythema infectiosum) is a viral infection caused by human parvovirus B19. It is more common in children than adults and usually affects children ages 4 to 14. The disease often starts with mild fever, headache, sore throat, and other flu-like symptoms. Children can also develop a bright red rash on the face that looks like “slapped cheeks”, along with a lacy or bumpy rash on the body, arms, and legs. In adults, joint aches are a common symptom. Rash and joint symptoms may develop several weeks after infection. About 20 to 30% of adults who are infected with parvovirus B19 will not have symptoms.
Fifth disease (erythema infectiosum) is a viral infection caused by human parvovirus B19. It is more common in children than adults and usually affects children ages 4 to 14. The disease often starts with mild fever, headache, sore throat, and other flu-like symptoms. Children can also develop a bright red rash on the face that looks like “slapped cheeks”, along with a lacy or bumpy rash on the body, arms, and legs. In adults, joint aches are a common symptom. Rash and joint symptoms may develop several weeks after infection. About 20 to 30% of adults who are infected with parvovirus B19 will not have symptoms.
Ingozi yokudlula i-parvovirus B19 isuka kumama iye enganeni icishe ibe ngama-33 %, kanti cishe u-3 % wabesifazane abanaleli gciwane bahlangabezana nezinkinga ezinganeni zabo. Uma umama etheleleka ngaphambi kokuba abe esezinsukwini ezingama-20 zokuqala kokukhulelwa, amathuba okuba nezinkinga ezifana nezinkinga zegazi nokunqwabelana koketshezi emzimbeni wengane ayanda. Ukuze siqale ukulawula lesi sifo, kufanele sihlole ukuthi isiguli sesachayeka yini ku-parvovirus ngokuhlola amasosha omzimba athile (IgM). Uma ukuhlolwa kungabonisi ukuchayeka esikhathini esidlule kodwa kukhombisa ukutheleleka kwakamuva, isiguli sidinga ukuqapha okuseduze phakathi nokukhulelwa, okuhlanganisa ukuskena okujwayelekile kwe-ultrasound ukuze kuhlolwe izinkinga ezithile zempilo yengane.
The rate of vertical transmission during maternal parvovirus B19 infection is estimated at 33%, with fetal complications occurring in 3% of infected women. Fetal complications comprising hemolysis, anemia, and nonimmune hydrops fetalis and fetal loss are more frequent when maternal infection occurs before 20 weeks of gestation. The first step in the management of this patient would be to obtain immunoglobulin (Ig) M and IgG titres against parvovirus to evaluate if the patient has had previous immunity against the disease. If results are negative for IgG but positive for IgM (ie, primary infection), this patient would need close obstetrical monitoring for the following weeks, including serial ultrasounds to rule out fetal anemia and hydrops fetalis.
The rate of vertical transmission during maternal parvovirus B19 infection is estimated at 33%, with fetal complications occurring in 3% of infected women. Fetal complications comprising hemolysis, anemia, and nonimmune hydrops fetalis and fetal loss are more frequent when maternal infection occurs before 20 weeks of gestation. The first step in the management of this patient would be to obtain immunoglobulin (Ig) M and IgG titres against parvovirus to evaluate if the patient has had previous immunity against the disease. If results are negative for IgG but positive for IgM (ie, primary infection), this patient would need close obstetrical monitoring for the following weeks, including serial ultrasounds to rule out fetal anemia and hydrops fetalis.
I-Fifth disease iqala ngemfiva enezinga eliphansi, ikhanda elibuhlungu, ukuqubuka, kanye nezimpawu ezinjengomkhuhlane, njengokugijima noma ikhala eliminyene. Lezi zimpawu ziyadlula; emva kwezinsuku ezimbalwa, ukuqubuka kuqala ukubonakala. Ukubomvu okugqamile kuvame ukuvela ebusweni, ikakhulukazi ezihlathini (ngakho-ke igama elithi “isifo sezihlathi ezimpama”). Ngaphandle kwezihlathi ezibomvu, izingane zivame ukuthola ukubomvu okucwebezelayo emzimbeni wonke, ikakhulukazi ezandleni, ebusweni, nasemilenzeni.
Lesi sifo ngokuvamile asibambezeli, kodwa kwabesifazane abakhulelwe, ukutheleleka esikhathini sokuqala sokukhulelwa kuye kwaxhunyaniswa ne-hydrops fetalis, okubangela ukuphuphuma kwesisu okungazelelwe.
○ Ukwelashwa
Akukho ukwelashwa okuqondile okudingekayo ngoba lesi sifo sivame ukuthuthuka ngokuhamba kwesikhathi.